Drug Trial Radar · NCT07105709
Open-label Extension Study in Participants With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Sep 15, 2028
Study completion Dec 8, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Alector Inc.
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.
Conditions
- Alzheimer's Disease
Interventions
GSK4527226Drug
GSK4527226 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (AEs) during the OLETime frame: Up to 112 Weeks
- Number of Participants with Adverse Event of Special Interest (AESIs) during the OLETime frame: Up to 112 Weeks
- Number of Participants with Serious Adverse Events (SAEs) during the OLETime frame: Up to 112 Weeks
- Number of Participants with Amyloid related imaging abnormalities (ARIAs) Including Severity during the OLETime frame: Up to 112 Weeks
Locations
33 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Maitland, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Stuart, Florida · Recruiting
GSK Investigational Site
Toms River, New Jersey · Recruiting
GSK Investigational Site
Staten Island, New York · Recruiting
GSK Investigational Site
Matthews, North Carolina · Recruiting
GSK Investigational Site
Oklahoma City, Oklahoma · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Fairfax, Virginia · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
Macquarie Park, New South Wales, Australia · Recruiting
GSK Investigational Site
Nedlands, Western Australia, Australia · Recruiting
GSK Investigational Site
Ottawa, Ontario, Canada · Recruiting
GSK Investigational Site
Peterborough, Ontario, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Greenfield Park, Quebec, Canada · Recruiting
GSK Investigational Site
Sherbrooke, Quebec, Canada · Recruiting
GSK Investigational Site
Oulu, Finland · Recruiting
GSK Investigational Site
Bergen, Norway · Recruiting
GSK Investigational Site
Oslo, Norway · Recruiting
GSK Investigational Site
Junggu, South Korea · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Gothenburg, Sweden · Recruiting
GSK Investigational Site
Malmö, Sweden · Recruiting
GSK Investigational Site
Stockholm, Sweden · Recruiting
GSK Investigational Site
Tainan, Taiwan · Recruiting
GSK Investigational Site
Taoyuan, Taiwan · Recruiting
GSK Investigational Site
Birmingham, United Kingdom · Recruiting
GSK Investigational Site
Bristol, United Kingdom · Recruiting
GSK Investigational Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.